The Food and Drug Administration on Wednesday approved Livsayis, a medicine Regeneron Pharmaceuticals developed for generalized myasthenia gravis, making it the first RNA interference therapy cleared for an autoimmune condition. The drug, formerly cemdisiran, silences production of the C5 protein implicated in the immune attack that drives the disease. It was discovered by Alnylam Pharmaceuticals and licensed to Regeneron in 2019 under a broad RNAi partnership.
The approval covers adult patients with the AChR antibody-positive form of the disease, the most common type. Livsayis is given by subcutaneous injection four times a year, a dosing edge over rivals including AstraZeneca’s once-weekly Klygefa and established C5 medicines from AstraZeneca and Argenx. A year’s supply carries a list price of $410,000, according to a Regeneron spokesperson. Alnylam receives a $25 million milestone payment tied to the approval and is eligible for sales royalties.
Analysts disagree on the launch. TD Cowen’s Tyler Van Buren projects $1.5 billion in peak annual sales, citing best-in-class efficacy and the dosing advantage in switch patients. RBC Capital Markets’ Brian Abrahams expects adoption to be measured at first against well-entrenched products, with physicians waiting to hear more on use and side effects. Before Livsayis, eight RNAi medicines had reached the market, most sold by Alnylam for rare diseases. For Regeneron, the drug is a first marketed RNAi product as biosimilar competition builds against its eye drug Eylea.